Key result
Changing anticoagulation regimens shows no benefit over maintaining current therapy for LAA thrombus resolution.
Why the study?
LAA thrombus can occur despite oral anticoagulation, but data on which anticoagulation strategy achieves the highest resolution rate are lacking.
Does changing the oral anticoagulation regimen improve LAA thrombus resolution rates compared to maintaining the same regimen in patients with atrial fibrillation and LAA thrombus despite OAC?
Cohort (n=216)
No
Does changing the oral anticoagulation regimen improve LAA thrombus resolution rates compared to maintaining the same regimen in patients with atrial fibrillation and LAA thrombus despite OAC?
In patients with atrial fibrillation and LAA thrombus despite ongoing oral anticoagulation, changing the anticoagulation regimen did not significantly improve thrombus resolution rates compared to continuing the existing therapy.
Answers are grounded in this paper and cite their sources.
Incomplete LAA thrombus resolution with anticoagulation warrants clinical caution; leaves open optimal regimen identification.
Introduction Left atrial appendage (LAA ) thrombus formation is a known complication of atrial fibrillation that may occur despite adequate oral anticoagulation (OAC) and is associated with elevated stroke risk and mortality. However, data on the anticoagulation strategy associated with the highest resultion rate is lacking. Therefore, we compared different therapeutic strategies in patients presenting with LAA thrombi under OAC therapy. Methods In this retrospective single-center study, 216 patients with atrial fibrillation and LAA thrombus despite OAC for more than three weeks were identified. Follow-up transesophageal echo (TEE) performed after a period of at least four weeks and was available for all patients. Clinical and echocardiographic parameters as well as anticoagulation regimen were compared between patients with and without thrombus resolution. Results Median age was 72 years (IQR 13), CHADS-Vasc score was elevated at 4 (IQR 2). Some patients consecutively underwent different treatment cycles. Each treatment cycle was analyzed, five treatment strategies were identified: Group 1 (Changing from VKA to NOAC), Group 2 (Maintaining VKA therapy with enhanced adherence/time in therapeutic range), Group 3 (Changing from NOAC to another NOAC), Group 4 (Maintaining the same NOAC therapy) and Group 5 (Changing from NOAC to VKA). 216 patients were included with 294 treatment cycles. The resolution rate was 51% (151/294) after a median treatment cycle duration of 61.5 days (IQR 50). Patients without thrombus resolution had higher CHADS-Vasc-Score and took amiodaron more frequently (see table 1). However, multivariate regression analysis identified no parameters predictive of LAA thrombus resolution. No statistical difference in resolution rate between the five anticoagulation strategies was observed (p=0.866, see diagram 1). After the first treatment cycle/second TEE, the resolution rate was highest at 55% and declined thereafter (see diagram 2). Conclusion This is the largest cohort of patients presenting with LAA thrombus despite ongoing OAC. Since no anticoagulation regimen proved superior, continuing the existing OAC appears to be a reasonable approach.
No takes yet. Share an insight, caveat, or question.
Schreiber et al. (2026) conducted a cohort in Atrial fibrillation and LAA thrombus despite OAC (n=216). Different anticoagulation strategies (changing or maintaining VKA/NOAC) vs. Other anticoagulation strategies was evaluated on LAA thrombus resolution (p=0.866). Different anticoagulation strategies (changing or maintaining VKA/NOAC) showed no statistical difference in LAA thrombus resolution rates.
Synapse has enriched 10 related papers. Consider them for comparative context: